

Organised by Pr Patrick Marcellin, APHC

14 & 15 January 2019

Palais des Congrès Paris

Elimination of HCV What we learned from ongoing national programs The Egyptian Experience

Ahmed El Ray Professor of Hepatogastroenterology Theodore Bilharz Research Institute Egypt There is no conflict of interest in this presentation

-Hepatitis C virus (HCV) infection is a major public health burden in Egypt, where it bears the highest prevalence rate in the world (*Blach et al*, 2016).

- In the past :
- The National Campaign for the Parenteral Treatment of Schistosomiasis
- At present :
- Nosocomial infection

HCV prevalence (DHS 2008-2015)

For Age group 15-59 years old



Until 2006, Egypt did not have a comprehensive national program for control of viral hepatitis - No large nationwide survey for the disease - No national guidelines for treatment

- Health insurance did not cover HCV therapy
- Limited infection control program

Egypt's national response to the HCV epidemic

- The foundation of the National Committee for the Control of Viral Hepatitis - NCCVH (2007)
 The foundation of the Egyptian National Control Strategy for Viral Hepatitis (2008)
- Trial for standardization of treatment protocols by putting national guidelines for HCV treatment

Current national treatment program centers





NCCVH 71 units

MOH 101 units

To deal with the large numbers of HCV patients, together with the fact health insurance covers a minority of the population,

A novel administrative solution was introduced for the first time in the health care setting in Egypt

A collection of network data of viral hepatitis treatment units was established, server located in Cairo

The network contains clinical information about patients at registration and during treatment for HCV

The Network Architecture



Patients' Journey



Low price of antiviral drugs in Egypt

The price of the brand antiviral drugs starting from the era of pegylated IFN and RBV to the DAAs is lower in the Egyptian market

During the era of Pegylated IFN – Ribavirin - Egyptian Biosimilar of Pegylated IFN

During the era of DAAs - Egyptian Generic of DAAs

The Egyptian Patent Office (EGYPO)

Low price of antiviral drugs in Egypt

A dramatic fall of the price of the generic molecules of the DAAs occurred during the last few months rendering the price of the combination (Sofo + Dacla) about 25 Euros per month.

DAAs available in Egypt

- Sofosbuvir (Sovaldi) + generic
- Daklatasvir (Daklinza) + generic
- Sofosbuvir + Ledipasvir (Harvoni) + generic
- Simeprevir (Olysio) No generic
- Ombitasvir / Paritaprevir / Ritonavir- (Querevo Viekira) No generic

HCV DAAs Prices for 12 weeks treatment (EGP) Brand vs. Generic



Chronology of treatment protocols implemented by the National Program

Date	Implemented protocol	Inclusion criteria
2007-2014	PegIFN-RBV	F1-F3 patients
October 2014-May 2015	Sofosbuvir-PegIFN-RBV	F3,F4 IFN tolerant
	Sofosbuvir-RBV	F3,F4 IFN intolerant up to Child B 8 (down to 7)
May 2015-November 2015	Sofosbuvir-PegIFN-RBV	F0-F4, normal synthetic function
	Sofosbuvir-Simeprevir	F0-F4, impaired synthetic function up to Child A6
November 2015	IFN-free regimen. Two DAAs ± RBV	F0-F4, impaired synthetic function up to B7. Higher Child in special centers

Number of treated patients through the Egyptian national treatment program with DAAs till the end of 2017 **1,344,496 Patients**



Known outcome in 165.349 patients



The fight against hepatitis C continues in Egypt to take a new dimension today.

After the public's rush to take Anti HCV treatment due to the availability and efficacy of generic DAAs, a large drop in the number of patients seeking treatment has been observed. The largest mass screening and treatment campaign allover the world

In October 2018, the Egyptian Ministry of Health launched a large mass screening and treatment campaign to eliminate hepatitis C in Egypt in the coming years



 The campaign began in October 2018 and is scheduled to end in April 2019.

The campaign (100 million health) was also designed to measure the blood pressure, the height and the weight (BMI) and to measure the blood sugar for all screened citizens

Phase	Period	No of Governorates
First Phase	October – December 2018	9 Governorates
Second phase	December- February 2019	11 Governorates
Third phase	March – April 2019	7 Governorates

Propagation

- sms messages (more than 3 millions)
- TV and Radio and newspapers
- Social media (facebook Twitter,.. etc,)
- Hotline
- Electronic website
- Points of screening (Fixed-mobile)

•Workers in big factories •University students School children •Rural areas Police sectors -Jails





0



دورك منتهاش

بصحتنا نبني بكرة

Click to edit Master text styles Second level Third level Fourth lev Fifth lev



فرصتك الان التحليل و العلاج **بالمجان** www.stophcv.eg





Individuals screened in phase I and II

- 13 Millions screened at the end of phase I
- More than 12 Millions were screened (until January 10th, 2019) by the ongoing phase II
- Eligible patients in phase I and phase II received the treatment.





اطمنا على صحة 1٨ مليون من بداية المبادرة







More than Citizens Screened since the start of the campaign in October 2018

More than 13 millions have been screened for HCV in phase I of the campaign



Results of the first phase

13.043.623 screened

502.022 HCV Ab +ve

People examined in the first phase of screening	HCV Positive	HCV negative	Percentage of HCV Ab +ve
of screening			

13.043 623	502.022	12. 541 601	3.84 %

Phase I screening (October - December 2018)

Percentage of HCV Ab positive in different Governorates



Phase II screening

- Scheduled from December 2018 until the end of February 2019
- More than 12 millions were screened until January the 11th 2019) by the ongoing phase II

Phase II screening (December 2018 - January 5th, 2019)

Percentage of HCV Ab in different Governorates



	No of screened	HCV Ab+ve	Percent
University student in 11 Governorates	77 730	1140	1.4% (varies between 0.3% to 4.2%)
School Student in 9 governorates	564 482	1959	0.3% (Varies between 0.3% to 0.8%)
Prisons in 4 Governorates	2152	345	16% (Varies between 14 – 24%)
Police stations in 11 Governorates	301 79	886	2.9% (Varies between 0.3% to 12.4%)

Friday January 11th 2019

Total patients screened : 25 939 324 HCV Ab positive : 1 064 277 HCV Ab negative : 24 875 047 HCV Ab prevalance : 4.1 %



🖻 🐳 😰 👬 💷 31% 🗎 10:36 am

☆ ③ 81.21.105.124/HCVSDE ③ :









WORLD NEWS DECEMBER 1, 2018 / 3:58 PM / 21 DAYS AGO

Millions flock to free tests as Egypt seeks to eradicate hepatitis C

Mahmoud Mourad, Lena Masri

3 MIN READ

MIT NAMA (Reuters) - When Houaida Mabrouk heard about a government campaigthat offers free hepatitis C screenings, she hesitated, afraid of testing positive. But af many from her community started visiting health clinics to get checked, she changed her mind.









MIT NAMA — When Houaida Mabrouk heard about a government campaign that offers free hepatitis C screenings, she hesitated, afraid of testing positive. But after many from her community started visiting health clinics to get checked, she changed her mind.

EGYPT, WITH HIGHEST HEP C RATE IN MIDDLE EAST, PLANS TO ERADICATE VIRUS

At least 11.5 million people have been screened in the new campaign, with 5 percent testing positive.

BY REUTERS / DECEMBER 3, 2018 16:54 🖶

2 minute read.



Close up of female doctor holding springe with injection (illustrative). (photo condit: DIG DIAGE/ASAP)

Conclusion

Enormous efforts have been made for trial for elimination of HCV in Egypt.

The recent campaign for HCV elimination in Egypt detected more than 1 million citizens HCV Ab positive in 100 days.

There is an urgent need for :

- Strengthening prevention efforts (more than 150 000 new cases of HCV per year in Egypt).

- Bringing down the costs of antiviral drugs where the poor population is the most likely to be infected by the virus.

